Literature DB >> 27570979

Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.

Moriah J Brier1, Dianne L Chambless1, Robert Gross2,3, Jinbo Chen4, Jun J Mao5.   

Abstract

BACKGROUND: Although poor adherence to hormonal therapies such as aromatase inhibitors (AIs) is widely documented, to the authors' knowledge less is known regarding whether health beliefs predict treatment nonadherence. The objective of the current study was to evaluate the relationship between health beliefs (perceived susceptibility to breast cancer, perceived benefits of AI treatment, and perceived barriers to AI treatment) and adherence to AIs.
METHODS: Postmenopausal women with early-stage, estrogen receptor-positive breast cancer who were currently receiving treatment with an AI completed the 3-factor Health Beliefs and Medication Adherence in Breast Cancer scale and questionnaires concerning their demographics and symptoms. Adherence data (treatment gaps and premature discontinuation) were abstracted from participants' medical charts. Logistic regression analyses were conducted to evaluate the relationship between health beliefs and adherence.
RESULTS: Among 437 participants, 93 (21.3%) were nonadherent. Those who perceived greater barriers to their AI treatment were more likely to demonstrate AI nonadherence behaviors by the end of their treatment period compared with those who reported fewer barriers to AI therapy (adjusted odds ratio, 1.71; 95% confidence interval, 1.03-2.86 [P = .04]). In contrast, perceived susceptibility to cancer recurrence and perceived benefits of AIs did not appear to predict AI adherence. Minority individuals were found to have lower perceived susceptibility to breast cancer recurrence and higher perceived barriers to AI treatment (P<.05 for both).
CONCLUSIONS: Greater perceived barriers appeared to predict nonadherence to AIs. Interventions addressing women's negative beliefs regarding the challenges of AI treatment are needed to help optimize adherence in survivors of breast cancer. Cancer 2017;169-176.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  aromatase inhibitors; arthralgia; medication nonadherence; patient compliance; psychosocial factors

Mesh:

Substances:

Year:  2016        PMID: 27570979      PMCID: PMC5161545          DOI: 10.1002/cncr.30318

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.

Authors:  Francesco Boccardo; Alessandra Rubagotti; Matteo Puntoni; Pamela Guglielmini; Domenico Amoroso; Angela Fini; Giuseppe Paladini; Mario Mesiti; Domenico Romeo; Michela Rinaldini; Simona Scali; Mauro Porpiglia; Chiara Benedetto; Nunzio Restuccia; Franco Buzzi; Roberto Franchi; Bruno Massidda; Vito Distante; Dino Amadori; Piero Sismondi
Journal:  J Clin Oncol       Date:  2005-07-11       Impact factor: 44.544

2.  Outline of a Fear-Avoidance Model of exaggerated pain perception--I.

Authors:  J Lethem; P D Slade; J D Troup; G Bentley
Journal:  Behav Res Ther       Date:  1983

3.  Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors.

Authors:  Melinda L Irwin; Brenda Cartmel; Cary P Gross; Elizabeth Ercolano; Fangyong Li; Xiaopan Yao; Martha Fiellin; Scott Capozza; Marianna Rothbard; Yang Zhou; Maura Harrigan; Tara Sanft; Kathryn Schmitz; Tuhina Neogi; Dawn Hershman; Jennifer Ligibel
Journal:  J Clin Oncol       Date:  2014-12-01       Impact factor: 44.544

Review 4.  Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research.

Authors:  Julia R Van Liew; Alan J Christensen; Janet S de Moor
Journal:  J Cancer Surviv       Date:  2014-07-02       Impact factor: 4.442

5.  Does patient education work in breast cancer? Final results from the global CARIATIDE study.

Authors:  Christos Markopoulos; Patrick Neven; Minna Tanner; Michael Marty; Rolf Kreienberg; Louise Atkins; Ann Franquet; Michael Gnant; Silvia Neciosup; Petra Tesarova; Sandro Barni; Veronique Deschamp
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

6.  A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use.

Authors:  Jun J Mao; Sharon X Xie; John T Farrar; Carrie T Stricker; Marjorie A Bowman; Deborah Bruner; Angela DeMichele
Journal:  Eur J Cancer       Date:  2013-10-24       Impact factor: 9.162

7.  Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.

Authors:  Vanessa B Sheppard; Leigh Anne Faul; George Luta; Jonathan D Clapp; Rachel L Yung; Judy Huei-Yu Wang; Gretchen Kimmick; Claudine Isaacs; Michelle Tallarico; William T Barry; Brandelyn N Pitcher; Clifford Hudis; Eric P Winer; Harvey J Cohen; Hyman B Muss; Arti Hurria; Jeanne S Mandelblatt
Journal:  J Clin Oncol       Date:  2014-06-16       Impact factor: 44.544

8.  Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.

Authors:  Aliza K Fink; Jerry Gurwitz; William Rakowski; Edward Guadagnoli; Rebecca A Silliman
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

9.  Missed opportunities: racial disparities in adjuvant breast cancer treatment.

Authors:  Nina A Bickell; Jason J Wang; Soji Oluwole; Deborah Schrag; Henry Godfrey; Karen Hiotis; Jane Mendez; Amber A Guth
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

10.  Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.

Authors:  Kannie Chim; Sharon X Xie; Carrie T Stricker; Qing S Li; Robert Gross; John T Farrar; Angela DeMichele; Jun J Mao
Journal:  BMC Cancer       Date:  2013-09-03       Impact factor: 4.430

View more
  14 in total

1.  Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.

Authors:  Ilana Graetz; Caitlin N McKillop; Edward Stepanski; Gregory A Vidal; Janeane N Anderson; Lee S Schwartzberg
Journal:  J Cancer Surviv       Date:  2018-02-28       Impact factor: 4.442

2.  Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.

Authors:  Moriah J Brier; Dianne L Chambless; Jinbo Chen; Jun J Mao
Journal:  Eur J Cancer       Date:  2018-01-09       Impact factor: 9.162

3.  Acupuncture versus medication for pain management: a cross-sectional study of breast cancer survivors.

Authors:  Ting Bao; Susan Q Li; Josh L Dearing; Lauren A Piulson; Christina M Seluzicki; Robert Sidlow; Jun J Mao
Journal:  Acupunct Med       Date:  2018-02-10       Impact factor: 2.267

Review 4.  Osteoporosis and musculoskeletal complications related to therapy of breast cancer.

Authors:  Johanna Suskin; Charles L Shapiro
Journal:  Gland Surg       Date:  2018-08

Review 5.  Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.

Authors:  Kate E Roberts; India T Adsett; Kirsty Rickett; Sophie M Conroy; Mark D Chatfield; Natasha E Woodward
Journal:  Cochrane Database Syst Rev       Date:  2022-01-10

6.  Oncotype testing in patients undergoing intraoperative radiation for breast cancer.

Authors:  Kelsey E Larson; Stephanie A Valente; Chirag Shah; Rahul D Tendulkar; Sheen Cherian; Jame Abraham; Courtney Yanda; Chao Tu; Jessica Echle; Stephen R Grobmyer
Journal:  Mol Clin Oncol       Date:  2018-08-23

7.  Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.

Authors:  Kate E Roberts; Kirsty Rickett; Sophie Feng; Dimitrios Vagenas; Natasha E Woodward
Journal:  Cochrane Database Syst Rev       Date:  2020-01-29

8.  Adherence to iron supplementation amongst pregnant mothers in Surabaya, Indonesia: Perceived benefits, barriers and family support.

Authors:  Mira Triharini; Agus Sulistyono; Merryana Adriani; Ni Ketut Alit Armini; Aria Aulia Nastiti
Journal:  Int J Nurs Sci       Date:  2018-07-05

9.  THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer.

Authors:  Andrew J Paladino; Janeane N Anderson; Rebecca A Krukowski; Teresa Waters; Mehmet Kocak; Carolyn Graff; Ryan Blue; Tameka N Jones; Joanne Buzaglo; Gregory Vidal; Lee Schwartzberg; Ilana Graetz
Journal:  BMC Health Serv Res       Date:  2019-12-19       Impact factor: 2.655

Review 10.  Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer.

Authors:  Aditi S Khatpe; Adedeji K Adebayo; Christopher A Herodotou; Brijesh Kumar; Harikrishna Nakshatri
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.